<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">33653604</PMID><DateCompleted><Year>2021</Year><Month>05</Month><Day>14</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1878-5883</ISSN><JournalIssue CitedMedium="Internet"><Volume>423</Volume><PubDate><Year>2021</Year><Month>Apr</Month><Day>15</Day></PubDate></JournalIssue><Title>Journal of the neurological sciences</Title><ISOAbbreviation>J Neurol Sci</ISOAbbreviation></Journal><ArticleTitle>Inhibition of HERV-K (HML-2) in amyotrophic lateral sclerosis patients on antiretroviral therapy.</ArticleTitle><Pagination><StartPage>117358</StartPage><MedlinePgn>117358</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jns.2021.117358</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0022-510X(21)00051-4</ELocationID><Abstract><AbstractText>Reactivation of Human Endogenous Retrovirus K (HERV-K), subtype HML-2, has been associated with pathophysiology of amyotrophic lateral sclerosis (ALS). We aimed to assess the efficacy of antiretroviral therapy in inhibiting HML-2 in patients with ALS and a possible association between the change in HML-2 levels and clinical outcomes. We studied the effect of 24-weeks antiretroviral combination therapy with abacavir, lamivudine, and dolutegravir on HML-2 levels in 29 ALS patients. HML-2 levels decreased progressively over 24&#xa0;weeks (P&#xa0;=&#xa0;0.001) and rebounded within a week of stopping medications (P&#xa0;=&#xa0;0.02). The majority of participants (82%), defined as "responders", experienced a decrease in HML-2 at week 24 of treatment compared to the pre-treatment levels. Differences in the evolution of some of the clinical outcomes could be seen between responders and non-responders: FVC decreased 23.69% (SE&#xa0;=&#xa0;11.34) in non-responders and 12.71% (SE&#xa0;=&#xa0;8.28) in responders. NPI score decreased 91.95% (SE&#xa0;=&#xa0;6.32) in non-responders and 53.05% (SE&#xa0;=&#xa0;10.06) in responders (P&#xa0;=&#xa0;0.01). Thus, participants with a virological response to treatment showed a trend for slower progression of the illness. These findings further support the possible involvement of HML-2 in the clinical course of the disease.</AbstractText><CopyrightInformation>Published by Elsevier B.V.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Garcia-Montojo</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Section of Infections of the Nervous System, National Institute of Neurological Disorders and Stroke, Bethesda, MD. USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fathi</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Section of Infections of the Nervous System, National Institute of Neurological Disorders and Stroke, Bethesda, MD. USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Norato</LastName><ForeName>G</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Section of Infections of the Nervous System, National Institute of Neurological Disorders and Stroke, Bethesda, MD. USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>B R</ForeName><Initials>BR</Initials><AffiliationInfo><Affiliation>Section of Infections of the Nervous System, National Institute of Neurological Disorders and Stroke, Bethesda, MD. USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rowe</LastName><ForeName>D B</ForeName><Initials>DB</Initials><AffiliationInfo><Affiliation>Department of Clinical Medicine, Macquarie University Centre for Motor Neuron Disease Research, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kiernan</LastName><ForeName>M C</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>Brain and Mind Centre, University of Sydney and Department of Neurology, Royal Prince Alfred Hospital, Sydney, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vucic</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, Westmead Hospital, University of Sydney, Sydney, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mathers</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, Calvary Health Care Bethlehem, Melbourne, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Eijk</LastName><ForeName>R P A</ForeName><Initials>RPA</Initials><AffiliationInfo><Affiliation>Department of Neurology, Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht, the Netherlands; Biostatistics &amp; Research Support, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Santamaria</LastName><ForeName>U</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Section of Infections of the Nervous System, National Institute of Neurological Disorders and Stroke, Bethesda, MD. USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rogers</LastName><ForeName>M-L</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>Centre for Neuroscience, Faculty of Medicine and Public Health, Flinders University, Adelaide, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Malaspina</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Blizard Institute, Queen Mary University of London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lombardi</LastName><ForeName>V</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Blizard Institute, Queen Mary University of London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mehta</LastName><ForeName>P R</ForeName><Initials>PR</Initials><AffiliationInfo><Affiliation>King's College London, Maurice Wohl Clinical Neuroscience Institute, Department of Basic and Clinical Neuroscience, London SE5 9RX, UK; King's College Hospital, Department of Neurology, London SE5 9RS, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Westeneng</LastName><ForeName>H-J</ForeName><Initials>HJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van den Berg</LastName><ForeName>L H</ForeName><Initials>LH</Initials><AffiliationInfo><Affiliation>Department of Neurology, Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al-Chalabi</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>King's College London, Maurice Wohl Clinical Neuroscience Institute, Department of Basic and Clinical Neuroscience, London SE5 9RX, UK; King's College Hospital, Department of Neurology, London SE5 9RS, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gold</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Blizard Institute, Queen Mary University of London, London, UK; King's College London, Maurice Wohl Clinical Neuroscience Institute, Department of Basic and Clinical Neuroscience, London SE5 9RX, UK; The Albion Centre and Faculty of Medicine and Health, The University of Sydney, Sydney, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nath</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Section of Infections of the Nervous System, National Institute of Neurological Disorders and Stroke, Bethesda, MD. USA. Electronic address: natha@ninds.nih.gov.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MALASPINA/APR13/817-791</GrantID><Acronym>MNDA_</Acronym><Agency>Motor Neurone Disease Association</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/R024804/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>TURNER/OCT15/972-797</GrantID><Acronym>MNDA_</Acronym><Agency>Motor Neurone Disease Association</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>ZIA NS003130</GrantID><Acronym>ImNIH</Acronym><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>02</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Neurol Sci</MedlineTA><NlmUniqueID>0375403</NlmUniqueID><ISSNLinking>0022-510X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>J Neurol Sci. 2021 Apr 15;423:117359</RefSource><PMID Version="1">33640108</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020077" MajorTopicYN="Y">Endogenous Retroviruses</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015658" MajorTopicYN="Y">HIV Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALS</Keyword><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">Antiretroviral</Keyword><Keyword MajorTopicYN="N">HERV-K</Keyword><Keyword MajorTopicYN="N">HML-2</Keyword></KeywordList><CoiStatement>DISCLOSURES. Authors declare no conflict of interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>12</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>1</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>2</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>3</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>5</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>3</Month><Day>3</Day><Hour>5</Hour><Minute>37</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33653604</ArticleId><ArticleId IdType="mid">NIHMS1678360</ArticleId><ArticleId IdType="pmc">PMC8009857</ArticleId><ArticleId IdType="doi">10.1016/j.jns.2021.117358</ArticleId><ArticleId IdType="pii">S0022-510X(21)00051-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Garcia-Montojo M, Doucet-O&#x2019;Hare T, Henderson L, Nath A. Human endogenous retrovirus-K (HML-2): a comprehensive review. Crit Rev Microbiol 2018;44:715&#x2013;738.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6342650</ArticleId><ArticleId IdType="pubmed">30318978</ArticleId></ArticleIdList></Reference><Reference><Citation>McCormick AL, Brown RH Jr., Cudkowicz ME, Al-Chalabi A Garson JA. Quantification of reverse transcriptase in ALS and elimination of a novel retroviral candidate. Neurology 2008;70:278&#x2013;283.</Citation><ArticleIdList><ArticleId IdType="pubmed">18209202</ArticleId></ArticleIdList></Reference><Reference><Citation>Steele AJ, Al-Chalabi A, Ferrante K, Cudkowicz ME, Brown RH Jr., Garson JA. Detection of serum reverse transcriptase activity in patients with ALS and unaffected blood relatives. Neurology 2005;64:454&#x2013;458.</Citation><ArticleIdList><ArticleId IdType="pubmed">15699374</ArticleId></ArticleIdList></Reference><Reference><Citation>Viola MV, Frazier M, White L, Brody J, Spiegelman S. RNA-instructed DNA polymerase activity in a cytoplasmic particulate fraction in brains from Guamanian patients. J Exp Med 1975;142:483&#x2013;494.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2189894</ArticleId><ArticleId IdType="pubmed">49390</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrews WD, Tuke PW, Al-Chalabi A, et al. Detection of reverse transcriptase activity in the serum of patients with motor neurone disease. J Med Virol 2000;61:527&#x2013;532.</Citation><ArticleIdList><ArticleId IdType="pubmed">10897073</ArticleId></ArticleIdList></Reference><Reference><Citation>MacGowan DJ, Scelsa SN, Imperato TE, Liu KN, Baron P, Polsky B. A controlled study of reverse transcriptase in serum and CSF of HIV-negative patients with ALS. Neurology 2007;68:1944&#x2013;1946.</Citation><ArticleIdList><ArticleId IdType="pubmed">17536052</ArticleId></ArticleIdList></Reference><Reference><Citation>Tam OH, Rozhkov NV, Shaw R, et al. Postmortem Cortex Samples Identify Distinct Molecular Subtypes of ALS: Retrotransposon Activation, Oxidative Stress, and Activated Glia. Cell Rep 2019;29:1164&#x2013;1177 e1165.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6866666</ArticleId><ArticleId IdType="pubmed">31665631</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayer J, Harz C, Sanchez L, et al. Transcriptional profiling of HERV-K(HML-2) in amyotrophic lateral sclerosis and potential implications for expression of HML-2 proteins. Mol Neurodegener 2018;13:39.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6091006</ArticleId><ArticleId IdType="pubmed">30068350</ArticleId></ArticleIdList></Reference><Reference><Citation>Garson JA, Usher L, Al-Chalabi A, Huggett J, Day EF, McCormick AL. Quantitative analysis of human endogenous retrovirus-K transcripts in postmortem premotor cortex fails to confirm elevated expression of HERV-K RNA in amyotrophic lateral sclerosis. Acta Neuropathol Commun 2019;7:45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6421708</ArticleId><ArticleId IdType="pubmed">30885274</ArticleId></ArticleIdList></Reference><Reference><Citation>Douville R, Liu J, Rothstein J, Nath A. Identification of active loci of a human endogenous retrovirus in neurons of patients with amyotrophic lateral sclerosis. Ann Neurol 2011;69:141&#x2013;151.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3052883</ArticleId><ArticleId IdType="pubmed">21280084</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Montojo M, Li W, Nath A. Technical considerations in detection of HERV-K in amyotrophic lateral sclerosis: selection of controls and the perils of qPCR. Acta Neuropathol Commun 2019;7:101.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6607509</ArticleId><ArticleId IdType="pubmed">31269986</ArticleId></ArticleIdList></Reference><Reference><Citation>Li W, Lee MH, Henderson L, et al. Human endogenous retrovirus-K contributes to motor neuron disease. Science Translational Medicine 2015;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6344353</ArticleId><ArticleId IdType="pubmed">26424568</ArticleId></ArticleIdList></Reference><Reference><Citation>Curzio DD, Gurm M, Turnbull M, et al. Pro-Inflammatory Signaling Upregulates a Neurotoxic Conotoxin-Like Protein Encrypted Within Human Endogenous Retrovirus-K. Cells 2020;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7407490</ArticleId><ArticleId IdType="pubmed">32629888</ArticleId></ArticleIdList></Reference><Reference><Citation>Arru G, Mameli G, Deiana GA, et al. Humoral immunity response to human endogenous retroviruses K/W differentiates between amyotrophic lateral sclerosis and other neurological diseases. Eur J Neurol 2018;25:1076&#x2013;e1084.</Citation><ArticleIdList><ArticleId IdType="pubmed">29603839</ArticleId></ArticleIdList></Reference><Reference><Citation>Tyagi R, Li W, Parades D, Bianchet MA, Nath A. Inhibition of human endogenous retrovirus-K by antiretroviral drugs. Retrovirology 2017;14:21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5361811</ArticleId><ArticleId IdType="pubmed">28330477</ArticleId></ArticleIdList></Reference><Reference><Citation>Gold J, Rowe DB, Kiernan MC, et al. Safety and tolerability of Triumeq in amyotrophic lateral sclerosis: the Lighthouse trial. Amyotroph Lateral Scler Frontotemporal Degener 2019;20:595&#x2013;604.</Citation><ArticleIdList><ArticleId IdType="pubmed">31284774</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludolph A, Drory V, Hardiman O, et al. A revision of the El Escorial criteria - 2015. Amyotroph Lateral Scler Frontotemporal Degener 2015;16:291&#x2013;292.</Citation><ArticleIdList><ArticleId IdType="pubmed">26121170</ArticleId></ArticleIdList></Reference><Reference><Citation>Laderoute MP, Larocque LJ, Giulivi A, Diaz-Mitoma F. Further Evidence that Human Endogenous Retrovirus K102 is a Replication Competent Foamy Virus that may Antagonize HIV-1 Replication. Open AIDS J 2015;9:112&#x2013;122.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4714383</ArticleId><ArticleId IdType="pubmed">26793281</ArticleId></ArticleIdList></Reference><Reference><Citation>Laderoute MP, Giulivi A, Larocque L, et al. The replicative activity of human endogenous retrovirus K102 (HERV-K102) with HIV viremia. AIDS 2007;21:2417&#x2013;2424.</Citation><ArticleIdList><ArticleId IdType="pubmed">18025878</ArticleId></ArticleIdList></Reference><Reference><Citation>Dube D, Contreras-Galindo R, He S, et al. Genomic flexibility of human endogenous retrovirus type K. J Virol 2014;88:9673&#x2013;9682.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4136327</ArticleId><ArticleId IdType="pubmed">24920813</ArticleId></ArticleIdList></Reference><Reference><Citation>Contreras-Galindo RA, Dube D, Fujinaga K, Kaplan MH, Markovitz DM. Susceptibility of Human Endogenous Retrovirus Type-K to Reverse Transcriptase Inhibitors. J Virol 2017.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5686744</ArticleId><ArticleId IdType="pubmed">28931682</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibbs JE, Rashid T, Thomas SA. Effect of transport inhibitors and additional anti-HIV drugs on the movement of lamivudine (3TC) across the guinea pig brain barriers. J Pharmacol Exp Ther 2003;306:1035&#x2013;1041.</Citation><ArticleIdList><ArticleId IdType="pubmed">12766261</ArticleId></ArticleIdList></Reference><Reference><Citation>Capparelli EV, Letendre SL, Ellis RJ, Patel P, Holland D, McCutchan JA. Population pharmacokinetics of abacavir in plasma and cerebrospinal fluid. Antimicrob Agents Chemother 2005;49:2504&#x2013;2506.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1140502</ArticleId><ArticleId IdType="pubmed">15917556</ArticleId></ArticleIdList></Reference><Reference><Citation>Scelsa SN, MacGowan DJ, Mitsumoto H, et al. A pilot, double-blind, placebo-controlled trial of indinavir in patients with ALS. Neurology 2005;64:1298&#x2013;1300.</Citation><ArticleIdList><ArticleId IdType="pubmed">15824372</ArticleId></ArticleIdList></Reference><Reference><Citation>Westarp ME, Bartmann P, Rossler J, et al. Antiretroviral therapy in sporadic adult amyotrophic lateral sclerosis. Neuroreport 1993;4:819&#x2013;822.</Citation><ArticleIdList><ArticleId IdType="pubmed">8394159</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Montojo M, De Las Heras V, Bartolome M, Arroyo R, Alvarez-Lafuente R. Interferon beta treatment: bioavailability and antiviral activity in multiple sclerosis patients. J Neurovirol 2007;13:504&#x2013;512.</Citation><ArticleIdList><ArticleId IdType="pubmed">18097882</ArticleId></ArticleIdList></Reference><Reference><Citation>Dominguez-Mozo MI, Garcia-Montojo M, De Las Heras V, et al. MHC2TA mRNA levels and human herpesvirus 6 in multiple sclerosis patients treated with interferon beta along two-year follow-up. BMC Neurol 2012;12:107.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3585729</ArticleId><ArticleId IdType="pubmed">23009575</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerlach N, Schimmer S, Weiss S, Kalinke U, Dittmer U. Effects of type I interferons on friend retrovirus infection. J Virol 2006;80:3438&#x2013;3444.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1440373</ArticleId><ArticleId IdType="pubmed">16537611</ArticleId></ArticleIdList></Reference><Reference><Citation>Beghi E, Chio A, Inghilleri M, et al. A randomized controlled trial of recombinant interferon beta-1a in ALS. Italian Amyotrophic Lateral Sclerosis Study Group. Neurology 2000;54:469&#x2013;474.</Citation><ArticleIdList><ArticleId IdType="pubmed">10668716</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowen LN, Tyagi R, Li W, et al. HIV-associated motor neuron disease: HERV-K activation and response to antiretroviral therapy. Neurology 2016;87:1756&#x2013;1762.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5089528</ArticleId><ArticleId IdType="pubmed">27664983</ArticleId></ArticleIdList></Reference><Reference><Citation>Lanznaster D, Hergesheimer RC, Bakkouche SE, et al. A beta 1&#x2013;42 and Tau as Potential Biomarkers for Diagnosis and Prognosis of Amyotrophic Lateral Sclerosis. Int J Mol Sci 2020;21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7216266</ArticleId><ArticleId IdType="pubmed">32326346</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller T, Cudkowicz M, Shaw PJ, et al. Phase 1&#x2013;2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS. N Engl J Med 2020;383:109&#x2013;119.</Citation><ArticleIdList><ArticleId IdType="pubmed">32640130</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>